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Abstract
Background: We previously determined that a weight-maintenance, non-ketogenic diet containing 30%
carbohydrate (CHO), 30% protein, 40% fat, (30:30:40) (LoBAG30) decreased glycated hemoglobin (%tGHb) from 10.8
to 9.1% over a 5 week period in subjects with untreated type 2 diabetes. Both the fasting glucose and postprandial
glucose area were decreased. Our objective in the present 10-week study was to determine: 1) whether the above
results could be maintained, or even improved (suggesting a metabolic adaptation) and 2) whether the subjects
would accept the diet for this longer time period. In addition, protein balance, and a number of other blood and
urine constituents were quantified at 5 and at 10 weeks on the LoBAG30 diet to address metabolic adaptation.
Methods: Eight men with untreated type 2 diabetes were studied over a 10-week period. Blood was drawn and
urine was collected over a 24 hour period at the beginning of the study with subjects ingesting a standard diet of
55% CHO, 15% protein, 30% fat, and at the end of 5 and 10 weeks following ingestion of a LoBAG30 diet.
Results: Body weight was stable. Fasting glucose decreased by 19% at week 5 and 28% at week 10; 24-h total
glucose area decreased by 27% at week 5 and 35% at week 10 compared to baseline. Insulin did not change.
Mean %tGHb decreased by 13% at week 5, 25% at week 10, and was still decreasing linearly, indicating that a
metabolic adaptation occurred. Serum NEFA, AAN, uric acid, urea, albumin, prealbumin, TSH, Total T3, free T4, B12,
folate, homocysteine, creatinine, growth hormone and renin did not differ between weeks 5 and 10. IGF-1
increased modestly. Urinary glucose decreased; urinary pH and calcium were similar.
Conclusions: A LoBAG30 diet resulted in continued improvement in glycemic control. This improvement occurred
without significant weight loss, with unchanged insulin and glucagon profiles, and without deterioration in serum
lipids, blood pressure or kidney function. Extending the duration of time on a LoBAG30 diet from 5 to 10 weeks had
little or no further effect on the hormones and metabolites measured, i.e. a metabolic equilibrium was established.
Background
Our interest over the past several years has been to
determine the metabolic consequences in people with
type 2 diabetes following ingestion of diets that are
lower in carbohydrate and higher in protein than those
recommended by government and professional organiza-
tions for the general population.
We previously had shown that the increase in blood
glucose concentration following a meal is due largely to
diet-derived glucose. This includes glucose per se, and
that from the hydrolysis of the disaccharides sucrose
and lactose. However, it is derived mainly from the
hydrolysis of dietary starch. The other monosaccharides
important in human nutrition, fructose and galactose,
had little effect on the blood glucose concentration
[1,2]. We also had shown previously that dietary protein
stimulates insulin secretion and either has no effect on
blood glucose, or lowers it [3-7].
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Since dietary glucose is largely responsible for raising
the plasma glucose after a meal, and dietary protein
either does not increase the glucose concentration, and
indeed may lower it, we have designed diets we refer to
as Low Biologically Available Glucose (LoBAG) diets. In
these diets we have reduced the carbohydrate content,
(particularly, starchy foods) and increased the protein
content. The LoBAG diets have been classified accord-
ing to the per cent of total energy as carbohydrate using
a subscript notation. Thus, a 20% carbohydrate diet is
referred to as LoBAG20, a 30% carbohydrate diet as
LoBAG30, and a 40% carbohydrate diet is referred to as
LoBAG40. The protein content in all of the above diets
is 30% of food energy, i.e. the protein content is 1 1/2 -
2 fold higher than that in a typical western diet.
All of these diets lowered the integrated 24-hour glu-
cose concentration and resulted in a significant decrease
in glycated hemoglobin [8-10].
Our previous studies were designed to be 5 weeks in
length because this is the time reported for the glycated
hemoglobin (GHb) to decrease by 50% of the ultimate
value (t1/2 = 33 days) [11] if the plasma glucose concen-
tration is rapidly decreased and is maintained at a lower
steady state. The new steady state occurs at ~100 days,
the time required for turnover of the red blood cell
mass. In the present study we have extended the time of
diet intervention from 5 weeks to 10 weeks.
The 24-hour profiles and integrated responses for glu-
cose, insulin, glucagon, non-esterified fatty acid (NEFA),
alpha amino nitrogen (AAN), uric acid and urea nitro-
gen, the creatinine clearance and amount of protein
metabolized as well as the a.m. fasting cholesterol, blood
pressure, weight, and glycated hemoglobin were deter-
mined. In addition, a number of other hormones and
metabolites determined in the study are presented.
Methods
Twelve male subjects were recruited and signed consent
forms. They were screened and found to be free of
hematologic abnormalities, liver disease, kidney disease,
macroalbuminuria (>300 mg/24 h), untreated thyroid
disease, congestive heart failure, angina, life-threatening
malignancies, proliferative retinopathy, diabetic neuropa-
thy, peripheral vascular disease, serious psychological
disorders, and had a body weight <136 kg (300 lb). The
inclusion criteria for the study were subjects with type 2
diabetes, c-peptide positive, whose fasting glucose con-
centration was less than 200 mg/dl (11.1 mmol/L), and
who were not taking oral hypoglycemic agents, and had
never taken insulin. All subjects had been taking one
oral hypoglycemic medication before enrolling in the
study. These medications were discontinued for varying
periods of time to allow the glycated hemoglobin to sta-
bilize before the study was begun. Diabetes medications
were discontinued because the objective of the study
was to determine the effect of the LoBAG diet per se,
without the confounding effect of a hypoglycemic agent.
Allowing the glycated hemoglobin to stabilize before
starting the study assured that the maximum effect of
the diet would be observed, i.e. the decrease due to the
diet was not masked by the increase due to discontinua-
tion of the medication. Other medications being taken
by the subjects were continued and remained
unchanged during the entire study. The study was
approved by the Department of Veterans Affairs Medi-
cal Center and the University of Minnesota Committees
on Human Subjects.
Eight subjects completed the study. Of the subjects
who did not complete the study, 1 subject gave
informed consent, but changed his mind before begin-
ning the study; 1 subject chose to discontinue the study
after 8 days; 1 subject developed influenza between
week 5 and week 10 of the study; 1 subject was discon-
tinued after 5 weeks on the study by the study team and
resumed his medication because his %tGHb had not
decreased during the preceding 5 weeks. In retrospect,
the %tGHb had not stabilized after discontinuing the
oral hypoglycemic medication before instituting the diet.
It should be added that in none of our previous studies
have subjects not completed the study, nor have we dis-
continued the study for any patient. Patient characteris-
tics are given in Table 1.
As indicated previously, a six-day rotating menu was
used which was calculated to consist of 30% carbohy-
drate, 30% protein, 40% fat (10% saturated fat)
(LoBAG30) [10]. The diet contains foods typical of those
consumed by our patient population. Dietary prefer-
ences were accommodated whenever possible. All food
was provided to the subjects. The total food energy of
the diet was individualized to insure that each subject
remained weight stable during the study. Our protocol
differs from others in the literature using a high protein-
low carbohydrate diet ([12], and reviewed in this paper),
in that our subjects are weight stable during the study.
This was done to eliminate the potential confounding
effect of weight loss on blood glucose control.
The protocol used was essentially as described pre-
viously [10]. Briefly, blood was drawn for 24-hour profiles
of glucose, insulin, C-peptide, glucagon, triacylglycerol,
alpha amino acid nitrogen (AAN), non-esterified fatty
acids (NEFA), uric acid, urea nitrogen, and creatinine at
the beginning of the study with subjects ingesting a con-
trol diet of 15% protein, 55% carbohydrate, 30% fat.
Thereafter subjects ingested a LoBAG30 diet, for which
we provided all of the food. At the end of weeks 5 and
10, blood was drawn again for the 24-hour profiles indi-
cated above. During each 24-hour data collection period,
urine was collected for determination of microalbumin,
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calcium, creatinine, glucose, pH, potassium, sodium, urea
and uric acid. Glycated hemoglobin was determined
weekly. In contrast to the previous 5-week study, the pre-
sent study was designed to be an intervention only study.
A control diet arm was not included in the current study
because we had shown previously that a LoBAG30 diet
improved blood glucose control compared to a control
diet [10]
Total glycohemoglobin was measured using boronate-
affinity high performance liquid chromatography (Biorad
Labs, Hercules, CA). During the study period, the
laboratory changed methods to an ion-exchange HbA1c
method. A conversion table was developed in order to
adjust the ion-exchange data to the boronate affinity
method data. Since the majority of the data were
obtained with the original method, the data in this
paper are reported as total glycohemoglobin. Serum glu-
cose concentrations were determined using a hexokinase
method on an Abbott Architect analyzer (Abbott
Laboratories, Abbott Park, IL). Serum immunoreactive
insulin was determined using an automated chemilumi-
nescent assay on a DPC IMMULITE platform (Diagnos-
tic Products Corp, Los Angeles, CA). Glucagon and C-
peptide were determined by radioimmunoassay using
kits from Linco Research (a subsidiary of Millipore, Inc.
Billerica, MI). The plasma and urine creatinine, plasma
urea nitrogen and uric acid were determined with an
automated method on an Ortho-Clinical Diagnostics
Vitros 950 analyzer (Raritan, NJ). NEFAs were measured
enzymically using a kit manufactured by Wako Chemi-
cals (Richmond, VA); total alpha amino nitrogen con-
centration by the method of Goodwin, which is a
measure of the total amino acids; plasma TSH, total
triiodothyronine (T3) and free thyroxine (T4) by Chemi-
flex (Abbott Architect, Abbott Park, IL), growth hor-
mone (Quest, New Brighton, MN) B12 and folate by
chemiluminescence (Diagnostic Products, Los Angeles,
CA); IGF-1 by RIA (Quest); homocysteine by HPLC
(Hewlett-Packard, Palo Alto, CA); microalbumin using a
Beckman-Coulter array 360 analyzer (Fullerton, CA);
urinary calcium and magnesium colorimetrically on a J
& J Vitros Instrument (J & J Engineering, Poulsbo, WA).
Weight was determined on a digital scale (Scalitronix,
White Plains, NY) in street clothes without shoes. Lean
body mass was determined by bioelectric impedance
(RJL Systems instrument, Clinton Town, MI). Blood
pressure was determined using an automatic Dinemap
Instrument (Critikon/Mediq, Pennsauken, NJ).
For quantitation of data obtained over the 24-hour
period, all of the net 24-hour incremental area responses
were calculated using the overnight fasting value as
baseline. Total 24-hour area responses also were calcu-
lated, using zero as the baseline. Both area calculations
were done using a computer program based on the tra-
pezoid rule [13]. The total amount of protein deami-
nated was determined by quantifying the urine urea
nitrogen excreted over the 24 hours of the study in
addition to the amount of urea nitrogen retained endo-
genously. The latter was calculated by determining the
difference in plasma urea nitrogen concentration
between the fasting baseline at the beginning and at the
end of each 24-hour study period, and correcting for
plasma water by dividing by 0.94. In this calculation, it
is assumed that there is a relatively rapid and complete
Table 1 Patient Characteristics
Subject Age Ht Ht Wt Wt BMI %
tGHb
Duration Concomitant Medications
Inches Cm Lb Kg T2DM Diseases
1 67 70 177.8 208.2 94.5 29.9 9.7 3 yr HT, BPH, osteoarthritis, gout,
GERD
terzosin, omeprazole, finisteride, ASA
2 65 70 177.8 165.8 75.3 23.8 11.2 4 yr HT, TBI none
3 58 70 177.8 241.2 109.5 34.6 9.3 4 yr HT, DJD, hyperlipidemia lisinopril, ranitidine, simvastatin
4 67 65.5 166.4 181.4 82.4 29.8 10.2 4 yr HT, hyperlipidemia gemfibrozil, losartan
5 60 71 180.3 185.0 84.0 25.8 9.8 5 yr HT, hyperlipidemia calcium/vit D, lisinopril, simvastatin,
naproxan, testosterone
6 69 68 172.7 183.4 83.3 27.9 8.6 6 yr HT, osteoarthritis, TIA,
hypercholesterolemia
lisinopril, amlodipine, atenolol
7 48 66 167.6 200.4 92.4 32.8 9.2 2 yr HT lisinopril
8 69 70 177.8 206.6 93.8 29.7 11.8 5 yr HT, BPH, back pain losartan, naproxan
Abbreviations:
HT: hypertension
BPH: benign prostatic hypertrophy
TBI: traumatic brain injury
DJD: degenerative joint disease
TIA: transient ischemic attack
GERD: gastro-esophageal reflux disease
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equilibration of urea in total body water. Total body
water as a percentage of body weight was calculated
using the equation of Watson et al. [14]. The overall
assumption is that a change in plasma urea concentra-
tion is indicative of a corresponding change in total
body water urea concentration. In these 24-hour studies,
the beginning and ending plasma urea nitrogen concen-
trations were essentially identical, indicating no reten-
tion of urea. The sum of total urea nitrogen in urine
and body water was divided by 0.86 to account for 14%
being lost to metabolism in the gut [15].
Statistics were determined by Student’s t test for
paired variates, comparing the results following 10
weeks on the LoBAG30 diet to those following 5 weeks
on the diet. A P value of <0.01 is the criterion for signif-
icance, because of the number of comparisons. Data are
presented as means ± SEM. Prism 4 software was used
(Graphpad Software, Inc. San Diego, CA) for the iMac
computer (Apple, Cupertino, CA).
Results
Weight
The subjects’ initial mean body weight was 199 lbs
(range 165-241 lbs) (90 kg; range 75-109 kg). The mean
final weight was 197 lbs (range 166-241 lbs) (89 kg;
range 75-109). Thus, the average body weight remained
essentially stable during the 10-week study period.
Glucose
The initial mean fasting glucose concentration was 201
± 13 mg/dl (11.2 ± 0.7 mmol/L) (Figure 1). After five
weeks on the diet, the fasting glucose concentration had
decreased to 163 ± 12 mg/dl (9.1 ± 0.7 mmol/L). After
10 weeks it had decreased significantly to 145 ± 12 mg/
dl (8.1 ± 0.6 mmol/L) (P = 0.02).
The postprandial glucose excursions decreased after 5
weeks on the LoBAG30 diet, as reported previously [10].
The excursions at 10 weeks were the same as at the
5-week time point. (Please see Figure 2, Figure 3, and
Figure 4 for data on individual patients at baseline, week 5,
and week 10, respectively.)
The mean net 24-hour integrated glucose area
responses, using the fasting value as baseline, were 944
± 234, 321 ± 185, 326 ± 134 mg•hr/dl (50 ±13; 18 ± 10;
18 ± 7 mmol•hr/L) for the baseline, 5 week and
10 week time periods, respectively. At 5 and 10 weeks
this represented a 66 and 65% decrease in net areas,
respectively (Figure 1, left inset).
The mean total 24-hour integrated glucose area
response was initially 5814 ± 457 mg•h/dl (323 ± 25
mmol•hr/L). After 5 weeks it was 4230 ± 329 mg•h/dl
(235 ± 18 mmol•hr/L), a 27% decrease. At 10 weeks it
had decreased further to 3805 ± 309 mg•hr/dl (211 ± 17
mmol•hr/L). This represents an additional 10% decrease
in response, which was statistically significant (P = 0.03)
(Figure 1 insert, right).
Glycated Hemoglobin
The mean glycated hemoglobin decreased from 10.0% at
baseline to 8.7% at 5 weeks. At the end of 10 weeks it
had decreased to 7.5% (P < 0.002) (Figure 5).
Insulin
The mean fasting insulin concentrations were similar
before and after 5 weeks and 10 weeks on the diet, as
were the excursions after meals (Figure 6). The mean
net and total 24-hour integrated insulin areas were
essentially the same at baseline, and at 5 and 10 weeks
(Figure 6 inserts).
The C-peptide excursions were similar to those of
insulin (data not shown).
Glucagon
The mean fasting glucagon concentration was not sig-
nificantly different at baseline, 5 weeks, or 10 weeks
after the LoBAG30 diet (89 ± 20, 104 ± 19, and 85 ± 18
pg/ml, respectively). The net area response increased
progressively from baseline to 5 weeks, and again at 10
weeks, but these increases were not statistically signifi-
cant. The total glucagon area responses were all similar
(Figure 7, insert).
Triacylglycerol
The mean fasting triacylglycerol concentration decreased
from a baseline of 159 ± 22 to 119 ± 19 mg/dl at
5 weeks (1.50 ± 0.22 to 119 ± 0.19 mmol/L). It
decreased further at 10 weeks to a mean of 105 ± 14
mg/dl (1.05 ± 0.14 mmol/L) (Figure 8). (P = 0.09). The
net triacylglycerol area responses were nearly identical.
The total triacylglycerol area responses decreased from
4950 ± 640 at baseline to 4039 ± 164 at 5 weeks and
3575 ± 494 mg•hr/dl at 10 weeks (49.5 ± 6.4 at baseline
to 40.39 ± 1.64 at 5 weeks and 35.75 ± 494 mmol•hr/L
at 10 weeks). The decrease between weeks 5 and 10
approached statistical significance (P = 0.06) (Figure 8,
insert).
NEFA
The mean fasting NEFA (non-esterified fatty acid) con-
centration was highest at baseline, lower after 5 weeks
and lowest after 10 weeks on the diet (Figure 9). How-
ever, these differences were not statistically significant
(P = 0.51). A similar decrease in fasting NEFA following
ingestion of the LoBAG30 diet also was observed in our
previous 5-week study [16]. In the 24-hour profile, the
NEFA concentrations decreased after meals, as expected,
and then transiently increased before the next meal. A
nadir was reached after the evening meal, followed by a
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return to baseline by 0800 the following morning. Both
the integrated net area and total 24-hour NEFA area
responses were similar following 5 and 10 weeks on
the LoBAG30 diet (Figure 9, inserts). When the 5- &
10-week net area responses were combined and com-
pared to the baseline area, there were no differences
(p value = 0.27).
NEFA vs Insulin
The NEFA response following meals is essentially the
reciprocal of the insulin response following meals at
baseline (Figure 10 top), 5 weeks (Figure 10 middle) and
10 weeks (Figure 10 bottom), as expected.
AAN
The mean fasting alpha amino acid nitrogen concentra-
tions were similar before the diet and after 5 weeks or
after 10 weeks on the diet (Figure 11). Both the inte-
grated net and total area responses at 5 & 10 weeks
were significantly increased compared to baseline
(P < 0.01) (Fig. 11, inserts). However, the net and total
area responses were similar after 5 and after 10 weeks
on the diet.
Uric Acid
The mean fasting uric acid concentration was modestly,
but not significantly higher after 5 or 10 weeks on the
diet (p = 0.14) (Figure 12, top). In the 24-hour profiles,
the uric acid concentration decreased during the day,
regardless of the diet, or the length of time on the
LoBAG30 diet. The decrease during the day was similar
to that noted previously in the 5 week study [16]. The
reason for the decrease is unknown, unless it is a dilu-
tional effect. The net 24-hour area was negative, due to
the decrease during the day, and was similar at baseline,
5 and 10 weeks (Figure 12, top insert). The total
24-hour areas were not statistically significantly different
between baseline, 5 and 10 weeks (Fig. 12 top, insert).
Figure 1 Mean serum glucose concentration at baseline while on the control diet, (closed circles) and after 5 weeks (open triangles)
and after 10 weeks (closed triangles) on the LoBAG30 diet. n = 8 subjects. The letters on the x axis indicate time of ingestion of Breakfast,
Lunch, Dinner, and Snack. Inset left - mean net integrated 24-hour area response (using the fasting value as baseline). Inset right - mean total
integrated 24-hour area response (using zero as baseline).
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Figure 2 24-hour glucose response at baseline for 8 individual subjects. The letters on the x axis indicate time of ingestion of Breakfast,
Lunch, Dinner, and Snack.
Figure 3 24-hour glucose response at 5 weeks for 8 individual subjects. The letters on the x axis indicate time of ingestion of Breakfast,
Lunch, Dinner, and Snack.
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Urea Nitrogen
The mean fasting plasma urea nitrogen concentration
was higher after 5 and 10 weeks on the diet compared
to baseline (Figure 12, bottom). The concentrations at 5
and 10 weeks were not different from one another, but
were statistically significantly increased compared to
baseline (P = 0.004). In the 24-hour profiles, there was a
very modest increase in urea nitrogen concentration
during the day, with a return to baseline by 0800 the
following morning. The responses at 5 and 10 weeks
were nearly identical. The net 24-hour urea nitrogen
area response was essentially zero at baseline, 5 and 10
Figure 4 24-hour glucose response at 10 weeks for 8 individual subjects. The letters on the x axis indicate time of ingestion of Breakfast,
Lunch, Dinner, and Snack.
Figure 5 Mean percentage total glycated hemoglobin (%tGHb) response during the 10 weeks of the LoBAG30 diet.
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Figure 6 Mean serum insulin concentration at baseline while on the control diet (closed circles), and after 5 weeks (open triangles)
and after 10 weeks (closed triangles) on the LoBAG30 diet. n = 8 subjects. The letters on the x axis indicate time of ingestion of Breakfast,
Lunch, Dinner, and Snack. Inset left - mean net integrated 24-hour area response (using the fasting value as baseline). Inset right - mean total
integrated 24-hour area response (using zero as baseline).
Figure 7 Mean plasma glucagon concentration at baseline while on the control diet (closed circles), and after 5 weeks (open
triangles) and after 10 weeks (closed triangles) on the LoBAG30 diet. n = 8 subjects. The letters on the x axis indicate time of ingestion of
Breakfast, Lunch, Dinner, and Snack. Inset left - mean net integrated 24-hour area response (using the fasting value as baseline). Inset right -
mean total integrated 24-hour area response (using zero as baseline).
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Figure 8 Mean triacylglycerol concentration at baseline while on the control diet (closed circles), and after 5 weeks (open triangles)
and after 10 weeks (closed triangles) on the LoBAG30 diet. n = 8 subjects. The letters on the x axis indicate time of ingestion of Breakfast,
Lunch, Dinner, and Snack. Inset left - mean net integrated 24-hour area response (using the fasting value as baseline). Inset right - mean total
integrated 24-hour area response (using zero as baseline).
Figure 9 Mean plasma nonesterified fatty acid (NEFA) response at baseline while on a 55% carbohydrate, 15% protein, 30% fat diet
(closed circles), following 5 weeks (open triangles) or following 10 weeks (closed triangles) on a LoBAG30 diet. n = 8 subjects. The
letters on the x axis indicate time of ingestion of Breakfast, Lunch, Dinner, and Snack. Inset left - mean net integrated 24-hour area response
(using the fasting value as baseline). Inset right - mean total integrated 24-hour area response (using zero as baseline).
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Figure 10 Relationship between insulin and NEFA concentrations. Top - Baseline data while on a 55% carbohydrate, 15% protein, 30% fat
diet; Middle - following 5 weeks on a LoBAG30 diet; Bottom - following 10 weeks on a LoBAG30 diet. n = 8 subjects. The letters on the x axis
indicate time of ingestion of Breakfast, Lunch, Dinner, and Snack. Units are μU/ml for insulin (closed triangles), and μEq × 10-1/L for NEFA (open
circles).
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weeks (Figure 12, bottom, insert). The 24-hour total
area increased by ~50% after 5 and 10 weeks on the
LoBAG30 diet (Figure 12, bottom, insert). Again, the
increases at 5 and 10 weeks were not different from one
another, but were statistically significantly increased
compared to baseline (p = 0.0001).
Amount of Protein Ingested and Metabolized
The calculated total amount of protein ingested during
the 24-hour study periods at the beginning and at the
end of 5 and 10 weeks was compared with the total pro-
tein metabolized (Figure 13, top).
At the beginning of the study, during the first 24 hours
while ingesting the control (15% protein) meals, it was
calculated that 96 ± 3 g of protein were ingested and
92 ± 5 g were metabolized (96 ± 5%) (Figure 13, top). At
the end 5 weeks on the LoBAG30 diet, the calculated
mean protein ingested over 24 hours was 201 ± 7 g; that
metabolized was 141 ± 15 g (70 ± 7%). At the end of
10 weeks, 203 ± 9 g of protein were calculated to have
been ingested and 150 ± 12 g were calculated to have
been metabolized (75 ± 7%). Thus, the calculated percent
of protein metabolized at 5 and 10 weeks after ingestion
of the LoBAG30 diet was similar and less than that fol-
lowing the control diet.
Calculating the grams of protein metabolized/kg lean
body mass, yielded similar results (Baseline = 1.3 ± 0.1, 5
week = 2.0 ± 0.2, 10 week 2.2 ± 0.1 g/kg lean body mass).
IGF-1
The fasting serum IGF-1 concentration was significantly
higher after ingestion of the LoBAG30 diet, from a mean
at baseline of 112 ± 16 to 160 ± 26 at 5 weeks and to
171 ± 25 ng/ml 10 weeks (Figure 13, bottom). The dif-
ference between the 5 and 10-week values was statisti-
cally significant (p = 0.01), and both were significantly
increased compared to baseline (P ≤ 0.004 and
p ≤ 0.0008, respectively).
Other Hormones and Metabolites
Serum albumin was modestly higher at week 5 compared
to baseline or week 10 (Table 2). The increase at week 5
Figure 11 Mean alpha amino acid nitrogen (AAN, i.e. total amino acid) response at baseline while on a 55% carbohydrate, 15%
protein, 30% fat diet (closed circles), following 5 weeks (open triangles) or following 10 weeks (closed triangles) on a LoBAG30 diet.
n = 8 subjects. The letters on the x axis indicate time of ingestion of Breakfast, Lunch, Dinner, and Snack.
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was similar to the statistically significant increase we
reported previously [16]. Prealbumin was only modestly
higher at week 5 and similar to baseline at week 10. The
TSH, total T3. Free T4, B12, folate, homocysteine, growth
hormone and renin were similar at baseline, 5 and 10
weeks. None of the minor differences in hormones and
metabolites noted above were statistically significant. The
fasting total, LDL, HDL cholesterol remained essentially
unchanged over the 10 weeks of the study (Table 2). The
blood pressure also was unchanged (Table 2).
Urine Data
The total urine volume and sodium excretion were
modestly greater at 5 weeks and further increased at
Figure 12 Top. Mean plasma uric acid response at baseline while on a 55% carbohydrate, 15% protein, 30% fat diet (closed circles),
following 5 weeks (open triangles) or following 10 weeks (closed triangles) on a LoBAG30 diet. n = 8 subjects. The letters on the x axis
indicate time of ingestion of Breakfast, Lunch, Dinner, and Snack. Inset left - mean net integrated 24-hour area response (using the fasting value
as baseline). Inset right - mean total integrated 24-hour area response (using zero as baseline). Bottom: Mean urea nitrogen response at baseline
while on a 55% carbohydrate, 15% protein, 30% fat diet (closed circles), or following 5 weeks (open triangles) or following 10 weeks (closed
triangles) on a LoBAG30 diet. n = 8 subjects. The letters on the x axis indicate time of ingestion of Breakfast, Lunch, Dinner, and Snack. Inset left -
mean net integrated 24-hour area response (using the fasting value as baseline). Inset right - mean total integrated 24-hour area response (using
zero as baseline).
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10 weeks compared to baseline (Table 3). Potassium
excretion was little changed. Urinary calcium excretion
was modestly less after 5 weeks on the diet and
remained lower than the baseline value at 10 weeks, but
this was not statistically significant.
Urinary glucose excretion decreased significantly after
5 weeks on the LoBAG30 diet, as we reported previously,
and as expected [16]. It was decreased further after
10 weeks, however the difference between weeks 5 and
10 was not statistically significant.
Urea excretion increased significantly after 5 weeks on
the diet, as we reported previously [16]. It decreased
very modestly, although significantly at week 10 com-
pared to week 5 (p = 0.01). Uric acid excretion was
increased significantly after 5 weeks on the diet, again
confirming our previous data [16]. It then decreased
modestly, but not significantly at 10 weeks. The urinary
pH was essentially constant at all times measured
(Table 2).
Only three of the subjects had measurable urinary
microalbumin at the beginning of the study. Two of the
three subjects urinary micro- albumin was unmeasurable
by 10 weeks.
The creatinine clearance did not increase between
week 5 and week 10 (Table 3).
Discussion
As noted previously [10], when subjects consumed the
LoBAG30 diet for 5 weeks, the fasting glucose concentra-
tion was decreased, as was the net integrated glucose
area response. In the present study, the subjects ingested
foods from the same 6-day rotating menu, but over
10 weeks. The area responses using the fasting value as
baseline were the same at 5 and 10 weeks. These similar
postprandial responses can be explained by the fact that
the meals consumed at 5 and 10 weeks were very similar.
However, the fasting glucose concentration had
decreased at 10 weeks when compared to the mean
5 week value. Consequently, the total 24 hr integrated
glucose area response was significantly lower at 10
weeks compared to 5 weeks. Thus, a time-dependent
metabolic adaptation had occurred in these subjects, but
this was exclusively due to a decrease in the overnight
fasting glucose concentration. Whether the fasting con-
centration would continue to decrease if the diet was
continued for a longer period of time remains to be
determined.
As indicated in the introduction, our previous studies
were 5 weeks in duration because this represents
the t1/2 for the glycated hemoglobin to reflect a decrease
in glucose concentration to a new steady state if
the change is instantaneous or very rapid [11]. By
extending the study to 10 weeks, we were interested in
determining whether the %tGHb would indeed continue
to decrease as expected. We also were interested in
determining if the rate of change between weeks 5 and
10 would be greater than expected based on the
reported t1/2. If so, this would support the concept that
a metabolic change was taking place.
If the change in glycated hemoglobin is an exponential
function, the expected decrease at 10 weeks would be
1/2 of that observed at 5 weeks. The %tGHb decreased
from 10.0 at baseline to 8.7 at 5 weeks (Δ = 1.3). Thus
the predicted value at 10 weeks would be 1/2 of 1.3 or a
Figure 13 Top: Protein metabolized and protein ingested. n =
8 subjects. Bottom: Mean fasting (0800 hr) IGF-1 concentration at
baseline while on a 55% carbohydrate, 15% protein, 30% fat diet,
and 5 weeks and 10 weeks on a LoBAG30 diet. n = 8 subjects.
* indicates statistical significance P < 0.004.
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further decrease of 0.65, i.e. the 10-week value would be
8.05. The actual value was 7.5. Thus, the actual differ-
ence at 10 weeks (8.7 - 7.5 = 1.2) is 85% greater than
the predicted decrease of 0.65 based on the t1/2. Indeed,
the rate of change is linear from baseline to week 10
(r2 = 0.99). The reason the decrease in glycated hemo-
globin was linear and lower than predicted, we suspect,
is because there is a continuing metabolic adaptation in
these subjects as a result of a continuing decrease in
fasting glucose concentration over the period of the
study. This assumes that the change in diet resulted in a
very rapid decrease in post-prandial glucoses, but a
slower change in the fasting glucose. The latter is likely
to be due to a decrease in glucose appearance rate. This
is a reasonable expectation, but has not been tested.
Of interest, one of the subjects chose to continue on a
similar diet on his own. After 6 months, the %tGHb was
continuing to decrease. The initial glycated hemoglobin
Table 2 Hormones, Metabolites and BP
Baseline 5 Week LoBAG30 10 Week LoBAG30 P Value
Common SI Common SI Common SI
Albumin 4.4 ± 0.1 g/dl 44 ± 1 g/L 4.8 + 0.1 g/dl 48 ± 1 g/L 4.5 + 0.1 g/dl 45 ± 1 g/L 0.02
Pre-Albumin 21.3 ± 1.1 mg/dl 21.3 ± 1.1 mg/dl 24.1 + 1.9 mg/dl 24.1 + 1.9 mg/dl 22.3 + 1.5 mg/dl 22.3 + 1.5 mg/dl 0.18
TSH 1.67 ± 0.25 μIU/ml 1.67 + 0.25 mU/L 1.46 + 0.20 μIU/ml 1.46 + 0.20 mU/L 1.59 + 0.24 μIU/ml 1.59 + 0.24 mU/L 0.03
Total T3 88.9 ± 4.06 ng/dl 1.37 + 0.06 nM 86.3 + 4.01 ng/dl 1.33 + 0.06 nM 94.0 + 3.51 ng/dl 1.44 + 0.05 nM 0.04
Free T4 0.97 ± 0.08 ng/dl 12.5 + 1.03 pM 0.97 + 0.03 ng/dl 12.5 + 0.39 pM 0.93 + 0.05 ng/d 12.0 + 0.64 pM 0.20
B 12 316 ± 45 pg/ml 223 + 33 pM 346 + 49 pg/ml 255 + 36 pM 336 + 53 pg/ml 248 + 39 pM 0.37
Folate 14.9 ± 1.5 ng/ml 33.8 + 3.40 nM 14.9 + 1.5 ng/ml 33.8 + 3.39 nM 13.3 + 1.3 ng/ml 30.1 + 2.95 nM 0.09
Homocysteine 138 ± 13.0 μg/dl 10.2 + 0.96 μM 146 + 10.4 μg/dl 10.8 + 0.77 μM 139 + 18.0 μg/dl 10.3 + 1.33 μM 0.24
Creatinine 1.0 ± 0.03 mg/dl 88.4 + 2.65 μM 1.0 + 0.04 mg/dl 88.4 + 3.54 μM 1.0 + 0.04 mg/dl 88.4 + 3.54 μM 0.09
Growth Hormone 0.2 ± 0.03 ng/ml 0.2 ± 0.03 μg/L 0.2 ± 0.06 ng/ml 0.2 ± 0.06 μg/L 0.3 ± 0.10 ng/ml 0.3 ± 0.10 μg/L 0.16
Renin 0.83 ± 0.34 ng/ml 0.83 ± 0.34 ng/ml 0.99 ± 0.37 ng/ml 0.99 ± 0.37 ng/ml 1.18 ± 0.75 ng/ml 1.18 ± 0.75 ng/ml 0.29
Lipids
Total Cholesterol 161 ± 11.8 mg/dl 4.2 ± 0.31 mM 159 ± 16.2 mg/dl 4.1 ± 0.42 mM 156 ± 12.9 mg/dl 4.0 ± 0.33 mM 0.96
LDL-Cholesterol 97 ± 8.5 mg/dl 2.5 ± 0.22 mM 105 ± 14.0 mg/dl 2.7 ± 0.36 mM 103 ± 11.3 mg/dl 2.7 ± 0.29 mM 0.88
HDL-Cholesterol 32 ± 1.7 mg/dl 0.8 ± 0.04 mM 31 ± 0.8 mg/dl 0.8 ± 0.02 mM 32 ± 1.7 mg/dl 0.8 ± 0.04 mM 0.93
BP
Blood Pressure (s) 135 ± 4.1 mm Hg 135 ± 5.3 mm Hg 136 ± 4.0 mm Hg 0.99
Blood Pressure (d) 82 ± 2.6 mm Hg 82 ± 3.6 mm Hg 74 ± 2.9 mm Hg 0.15
n = 8
Table 3 24 Hour Urine
Baseline 5 Week LoBAG30 10 Week LoBAG30 P Value*
Common SI Common SI Common SI
Volume 3670 ± 494 ml 3670 ± 494 ml 3811 ± 633 ml 3811 ± 633 ml 4197 ± 689 ml 4197 ± 689 ml 0.11
Sodium 5451 ± 759 mg 237 ± 33 mmol 6417 ± 690 mg 279 ± 30 mmol 7337 ± 1139 mg 319 ± 50 mmol 0.06
Potassium 3822 ± 335 mg 98 ± 8.6 mmol 4017 ± 359 mg 103 ± 9.2 mmol 3900 ± 316 mg 100 ± 8.1 mmol 0.31
Calcium 249 ± 48 mg 6.2 ± 1.2 mmol 210 ± 41 mg 5.3 ± 1.0 mmol 229 ± 33 mg 5.7 ± 0.8 mmol 0.28
Glucose 33.3 ± 13.2 g 185 ± 73 mmol 5.4 ± 3.6 g 30.0 ± 20 mmol 2.8 ± 1.8 g 15.7 ± 9.7 mmol 0.15
Creatinine 1724 ± 113 mg 6.4 ± 1.0 mmol 2109 ± 173 mg 18.7 ± 1.5 mmol 2076 ± 209 mg 18.4 ± 1.8 mmol 0.37
Urea 13.1 ± 0.8 g 0.22 ± 0.01 mol 22.3 ± 1.5 g 0.38 ± 0.03 mol 21.6 ± 1.8 g 0.37 ± 0.03 mol 0.01*
Uric Acid 720 ± 43 mg 4.3 ± 0.3 mmol 971 ± 59 mg 5.8 ± 0.4 mmol 957 ± 75 mg 5.7 ± 0.4 mmol 0.37
pH 6.1 ± 0.1 6.1 ± 0.1 6.2 ± 0.2 6.2 ± 0.2 6.3 ± 0.2 6.3 ± 0.2 0.26
μAlbumin 9 ± 3.4 mg 9 ± 3.4 mg 6 ± 1 mg 6 ± 1 mg 5 ± 0.2 mg 5 ± 0.2 mg 0.13
Creatinine Clearance** 117 ± 8.3 ml/min 144 ± 12.1 ml/min 148 ± 11.4 ml/min 0.12
*5 vs 10 weeks
n = 8
** Student’s t test on Creatinine Clearance: Baseline vs 5 weeks, p = 0.005; baseline vs 10 weeks, p = 0.002
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was 11.2%; at 6 months it was 6.5%, and the final after
one year was 6.0%. This occurred without weight loss.
In the present study, the fasting serum insulin concen-
tration changed very little from baseline to week 5, con-
firming our previous report [10]. The fasting
concentration at 10 weeks also was similar. In addition,
there was little difference in the postprandial insulin
responses at baseline, 5 weeks, and 10 weeks. This is in
spite of the fact that the glucose concentrations decreased.
Our data suggest that insulin is more efficient in inhibiting
glucose production and/or accelerating glucose disposi-
tion. The mechanism remains to be determined.
Dietary protein is known to stimulate an increase in
circulating glucagon concentration acutely [17]. Of some
interest, the glucagon concentration increased progres-
sively throughout the day and did not return to the
baseline fasting value until the early morning hours.
This pattern is similar to that noted earlier in normal
young subjects [18]. However, the return was somewhat
delayed when the subjects were consuming the
LoBAG30 diet. We did observe a progressive increase in
postprandial glucagon area responses with the LoBAG30
diet [10]. However, the increase did not reach statistical
significance in either study. In addition, even though the
protein content was increased in the LoBAG30 diet com-
pared to the control diet, the total glucagon areas all
remained very similar. The metabolic consequences, if
any, of the sustained total circulating glucagon concen-
tration is unclear. In any regard, it did not prevent a
decrease in circulating glucose. It should be added that
we have provided evidence that modest, physiologic ele-
vations in glucagon concentration have little effect on
net hepatic glucose output [19].
The fasting triacylglycerol concentration at 5 weeks
was 25% less than at baseline. This is modestly less than
the 40% decrease we reported previously [10], but the
subjects in the current study started with a lower tria-
cylglycerol concentration at baseline (~159 vs. 190 mg/
dl). After 10 weeks on the LoBAG30 diet, the fasting
concentration decreased an additional 12%, again indi-
cating that a metabolic adaptation is occurring in these
subjects. Dietary carbohydrate is known to raise the
morning fasting triacylglycerol concentration [20]. Our
current data, and that reported previously, demonstrate
that lowering the carbohydrate content also lowers the
24 hour integrated triacylglycerol concentration.
The NEFA concentration decreased when the insulin
concentration increased, as expected. However, a thresh-
old insulin concentration above which the NEFA
decreased is not apparent. The general response is that
when the insulin concentration increased after meals,
the NEFA concentration decreased. As the insulin con-
centration decreased after the evening meal, the NEFA
concentration increased (Figure 7).
In spite of the increased fat content of the LoBAG 30
diet, the lipid profile did not change.
An increase in fasting IGF-1 concentration between
baseline and week 5 confirmed our previous data [16].
Indeed, we previously reported that increasing the pro-
tein content of the diet from 15% to 30% of total food
energy resulted in a 35% increase in IGF-1 concentration,
regardless of the carbohydrate:fat ratio of the diet
[21,22,16]. In the present study the increase at 5 weeks
was 43%. Interestingly, the concentration increased
another 7% by week 10, but the rate of increase was slow-
ing, suggesting a near maximal effect of the diet had
occurred at this time.
The serum albumin was increased at 5 weeks as we
noted previously [16]. However, in the present study, it
returned toward baseline at 10 weeks. The difference
between the increase at week 5 and the decrease at
week 10 approached statistical significance (P = 0.02).
There was no reason to suspect a decrease in plasma
volume at 5 weeks, or an increase in plasma volume at
10 weeks to explain the changes in albumin concentra-
tion. Thus, the return toward baseline could represent
another metabolic adaptation to the 30% protein diet.
When the subjects ingested the LoBAG30 diet for
5 weeks, the 24-hour urinary urea nitrogen increased, as
expected. The mean increase was only ~70% and not
2-fold, as would be expected with a doubling of the pro-
tein content of the diet. Interestingly, following an addi-
tional 5 weeks on the diet, the urinary urea nitrogen
excretion decreased very modestly, but this was statisti-
cally significant.
The protein balance, based on the urinary excretion of
urea, was positive following 5 weeks on the LoBAG30
diet, and was similar to that in our previous study
(30% vs 32%). At 10 weeks it was slightly less (25%)
(Figure 13). The fate of the nitrogen not excreted in the
urine remains unknown, but is consistent. The data
indicate that nitrogen was being retained and/or that it
was being lost from the gastrointestinal tract in the
feces. Loses from any other site would not be sufficient
for it to explain the difference. We did not attempt to
determine changes in body composition in this study,
but an exclusive gain in protein mass also would have
to be very large in order to explain the difference.
The creatinine, and uric acid excretion were similar at
5 and 10 weeks, indicating that there was no further
adaptation at 10 weeks.
Over the years the concept has developed that a high-
protein, “Western” diet would result in a systemic acido-
sis, result in calcium leaching from bone and increase
calcium excretion, all ultimately leading to a decrease in
bone mass (Reviewed in [23]). Evidence to refute this
concept was published by Bonjour [24]. In the present
study the urinary pH was unchanged, as noted by others
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[24], presumably because of ingestion of fruits and vege-
tables, which result in an increase in pH. Also, calcium
excretion was not increased. Several studies subse-
quently have reported that an increase in dietary protein
has a salutary effect on bone [25-31]. This has been
attributed to an increase in IGF-1 (reviewed in [32]), as
noted in the present study.
There was no significant difference in the serum
NEFA, AAN, uric acid, urea nitrogen, albumin, prealbu-
min, TSH, Total T3, free T4, B12, folate, homocysteine,
creatinine, growth hormone or renin between week 5
and week 10.
The literature on the effects of low carbohydrate diets
is increasing rapidly. A Medline search of “low carbohy-
drate diet” or “Diet, carbohydrate-restricted”, limited to
humans and English language, yielded 7 papers for the
year 2000: 32 for 2005: 81 for 2009. For 2010, through
July Week 1, the yield was 26. The majority of this lit-
erature contains studies employing weight loss.
Although a recent review reported that the beneficial
effects of carbohydrate restriction do not require weight
loss [33], the references cited [34-36], other than our
work, all had different experimental designs or different
primary outcome measures than those reported here.
Nevertheless, the review points out that data are accu-
mulating to suggest that carbohydrate restriction, with-
out weight loss, potentially has beneficial health effects.
Our studies, including the current 10-week study dif-
fer from most in the literature in several respects. First,
we make a conscious effort to keep subjects weight
stable during the study. Second, we provide all of the
food, and we use common foods, not synthetic diets.
Also we do not use supplements. Finally, we emphasize
keeping a pre-study activity level during the entire per-
iod of the study. By including all of these parameters in
the experimental design, we have been able to provide
sound scientific evidence that not only is blood glucose
control improved, evidenced by a decrease in total gly-
cated hemoglobin from 10.0 to 7.5, (Δ2.5%) in the pre-
sent study, but a metabolic adaptation had occurred
during that time that was the result of the dietary
intervention.
Conclusion
In summary, we have extended our study of a LoBAG30
diet from 5 weeks to 10 weeks. A further improvement
in glycemic control in subjects with untreated type 2
diabetes was observed, indicating a continuing metabolic
adaptation. This improvement in glucose control
occurred without significant weight loss, with
unchanged insulin and glucagon profiles, and without a
deterioration in serum lipids, blood pressure or in kid-
ney function. A LoBAG30 diet ingested for 10 weeks
resulted in a modest further increase in IGF-1. Urinary
glucose excretion decreased further at 10 weeks, as
would be expected with a continuing decrease in fasting
glucose and %tGHb. Twenty-four hour profiles of serum
NEFA, AAN, uric acid and urea nitrogen were
unchanged at 10 weeks compared with 5 weeks. The
per cent dietary protein accountable as urinary nitrogen
daily was only 68% at 5 weeks and only ~75% at 10
weeks. The fate of the remaining ingested protein
remains to be determined. A number of other blood
and urine constituents of interest were unchanged.
Lastly, the subjects were able to ingest a 30% carbohy-
drate, 30% protein, 40% fat diet for 10 weeks without
difficulty. Indeed, some subjects preferred it.
This provides further evidence to support the concept
that a LoBAG diet should be beneficial for some sub-
jects with type 2 diabetes.
Acknowledgements
This study was supported in part from merit review funds from the
Department of Veterans Affairs, and grants from the Minnesota Beef Council
and by the Beef Checkoff, through the National Cattlemen’s Beef Association.
We thank Jan Thurgood, B.S., Linda Hartich, M.T., the staffs of the Special
Diagnostic and Treatment Unit and the Clinical Chemistry and Nuclear
Medicine Laboratories for their excellent technical assistance. We also thank
Dr. Michael Kuzkowski for advice on statistical analysis of the data and Dave
Prentiss of the Medical Media Department for help with the figures. We
would particularly like to thank our volunteers for their dedication in making
these studies possible.
Author details
1Metabolic Research Laboratory and Section of Endocrinology, Metabolism &
Nutrition, VA Medical Center, Minneapolis, MN, USA. 2Department of Food
Science & Nutrition, University of Minnesota, St. Paul, MN, USA. 3Department
of Medicine, University of Minnesota, Minneapolis, MN, USA. 4Nutrition &
Food Service, VA Medical Center, Minneapolis, MN, USA.
Authors’ contributions
MCG and FQN contributed equally to the study i.e. experimental design,
obtaining funding, analyzing data and writing the manuscript. HH planned
the menus and met with the patients twice each week during the study.
All authors have read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 2 February 2010 Accepted: 29 July 2010
Published: 29 July 2010
References
1. Nuttall FQ, Khan MA, Gannon MC: Peripheral glucose appearance rate
following fructose ingestion in normal subjects. Metabolism 2000,
49:1565-1571.
2. Gannon MC, Khan MA, Nuttall FQ: Glucose appearance rate after the
ingestion of galactose. Metabolism 2001, 50:93-98.
3. Nuttall FQ, Mooradian AD, Gannon MC, Billington C, Krezowski P: Effect of
protein ingestion on the glucose and insulin response to a standardized
oral glucose load. Diabetes Care 1984, 7:465-470.
4. Krezowski PA, Nuttall FQ, Gannon MC, Bartosh NH: The effect of protein
ingestion on the metabolic response to oral glucose in normal
individuals. Am J Clin Nutr 1986, 44:847-856.
5. Gannon MC, Nuttall FQ, Neil BJ, Westphal SA: The insulin and glucose
responses to meals of glucose plus various proteins in type II diabetic
subjects. Metabolism 1988, 37:1081-1088.
6. Khan MA, Gannon MC, Nuttall FQ: Glucose appearance rate following
protein ingestion in normal subjects. J Am Coll Nutr 1992, 11:701-706.
Gannon et al. Nutrition & Metabolism 2010, 7:64
http://www.nutritionandmetabolism.com/content/7/1/64
Page 16 of 17
7. Gannon MC, Nuttall JA, Damberg G, Gupta V, Nuttall FQ: Effect of protein
ingestion on the glucose appearance rate in people with type 2
diabetes. J Clin Endocrinol Metab 2001, 86:1040-1047.
8. Gannon MC, Nuttall FQ, Saeed A, Jordan K, Hoover H: An increase in
dietary protein improves the blood glucose response in persons with
type 2 diabetes. Am J Clin Nutr 2003, 78:734-741.
9. Gannon MC, Nuttall FQ: Effect of a high-protein, low-carbohydrate diet
on blood glucose control in people with type 2 diabetes. Diabetes 2004,
53:2375-2382.
10. Nuttall FQ, Schweim K, Hoover H, Gannon MC: Effect of the LoBAG30 diet
on blood glucose control in people with type 2 diabetes. Br J Nutr 2008,
99:511-519.
11. Rech ME: Observations on the decay of glycated hemoglobin HbA1c in
diabetic patients. Exp Clin Endocrinol Diabetes 1996, 104:102-105.
12. Yancy WS, Foy M, Chalecki AM, Vernon MC, Westman EC: A low-
carbohydrate, ketogenic diet to treat type 2 diabetes. Nutr Metab (Lond)
2005, 2:34.
13. Gannon MC: A computer program to calculate the rate of appearance of
glucose in the peripheral circulation following infusion of labeled
glucose. Copyright, University of Minnesota, Minneapolis, MN 1991.
14. Watson PE, Watson ID, Batt RD: Total body water volumes for adult males
and females estimated from simple anthropometric measurements. Am
J Clin Nutr 1980, 33:27-39.
15. Hamberg O, Vilstrup H: Effects of insulin and glucose on urea synthesis in
normal man, independent of pancreatic hormone secretion. J Hepatol
1994, 21:381-387.
16. Nuttall FQ, Schweim K, Hoover H, Gannon MC: Metabolic effect of a
LoBAG30 diet in men with type 2 diabetes. Am J Physiol Endocrinol Metab
2006, 291:E786-791.
17. Unger RH, Orci L: Physiology and pathophysiology of glucagon. Physiol
Rev 1976, 56:778-826.
18. Ahmed M, Nuttall FQ, Gannon MC, Lamusga RF: Plasma glucagon and
alpha-amino acid nitrogen response to various diets in normal humans.
Am J Clin Nutr 1980, 33:1917-1924.
19. Nuttall FQ, Ngo A, Gannon MC: Regulation of hepatic glucose production
and the role of gluconeogenesis in humans: is the rate of
gluconeogenesis constant? Diabetes Metab Res Rev 2008, 24:438-458.
20. Ahrens EH Jr, Hirsch J, Oette K, Farquhar JW, Stein Y: Carbohydrate-
induced and fat-induced lipemia. Trans Assoc Am Physicians 1961,
74:134-146.
21. Nuttall FQ, Gannon MC, Saeed A, Jordan K, Hoover H: The metabolic
response of subjects with type 2 diabetes to a high-protein, weight-
maintenance diet. J Clin Endocrinol Metab 2003, 88:3577-3583.
22. Nuttall FQ, Gannon MC: The metabolic response to a high-protein, low-
carbohydrate diet in men with type 2 diabetes mellitus. Metabolism
2006, 55:243-251.
23. Barzel US, Massey LK: Excess dietary protein can adversely affect bone. J
Nutr 1998, 128:1051-1053.
24. Bonjour JP: Dietary protein: an essential nutrient for bone health. J Am
Coll Nutr 2005, 24:526S-536S.
25. Heaney RP: Protein intake and the calcium economy. J Am Diet Assoc
1993, 93:1259-1260.
26. Cooper C, Atkinson EJ, Hensrud DD, Wahner HW, O’Fallon WM, Riggs BL,
Melton LJ: Dietary protein intake and bone mass in women. Calcif Tissue
Int 1996, 58:320-325.
27. Promislow JH, Goodman-Gruen D, Slymen DJ, Barrett-Connor E: Protein
consumption and bone mineral density in the elderly: the Rancho
Bernardo Study. Am J Epidemiol 2002, 155:636-644.
28. Eastell R, Lambert H: Diet and healthy bones. Calcif Tissue Int 2002,
70:400-404.
29. Roughead ZK, Johnson LK, Lykken GI, Hunt JR: Controlled high meat diets
do not affect calcium retention or indices of bone status in healthy
postmenopausal women. J Nutr 2003, 133:1020-1026.
30. Wengreen HJ, Munger RG, West NA, Cutler DR, Corcoran CD, Zhang J,
Sassano NE: Dietary protein intake and risk of osteoporotic hip fracture
in elderly residents of Utah. J Bone Miner Res 2004, 19:537-545.
31. Dawson-Hughes B, Harris SS, Rasmussen H, Song L, Dallal GE: Effect of
dietary protein supplements on calcium excretion in healthy older men
and women. J Clin Endocrinol Metab 2004, 89:1169-1173.
32. Rizzoli R, Bonjour JP: Dietary protein and bone health. J Bone Miner Res
2004, 19:527-531.
33. Accurso A, Bernstein RK, Dahlqvist A, Draznin B, Feinman RD, Fine EJ,
Gleed A, Jacobs DB, Larson G, Lustig RH, Manninen AH, McFarlane SI,
Morrison K, Nielsen JV, Ravnskov U, Roth KS, Silvestre R, Sowers JR,
Sundberg R, Volek JS, Westman EC, Wood RJ, Wortman J, Vernon MC:
Dietary carbohydrate restriction in type 2 diabetes mellitus and
metabolic syndrome: time for a critical appraisal. Nutr Metab (Lond) 2008,
5:9.
34. Westman EC, Yancy WS Jr, Mavropoulos JC, Marquart M, McDuffie JR: The
effect of a low-carbohydrate, ketogenic diet versus a low-glycemic index
diet on glycemic control in type 2 diabetes mellitus. Nutr Metab (Lond)
2008, 5:36.
35. Allick G, Bisschop PH, Ackermans MT, Endert E, Meijer AJ, Kuipers F,
Sauerwein HP, Romijn JA: A low-carbohydrate/high-fat diet improves
glucoregulation in type 2 diabetes mellitus by reducing postabsorptive
glycogenolysis. J Clin Endocrinol Metab 2004, 89:6193-6197.
36. Sharman MJ, Kraemer WJ, Love DM, Avery NG, Gomez AL, Scheett TP,
Volek JS: A ketogenic diet favorably affects serum biomarkers for
cardiovascular disease in normal-weight men. J Nutr 2002, 132:1879-1885.
doi:10.1186/1743-7075-7-64
Cite this article as: Gannon et al.: Further decrease in glycated
hemoglobin following ingestion of a LoBAG30 diet for 10 weeks
compared to 5 weeks in people with untreated type 2 diabetes.
Nutrition & Metabolism 2010 7:64.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Gannon et al. Nutrition & Metabolism 2010, 7:64
http://www.nutritionandmetabolism.com/content/7/1/64
Page 17 of 17
